Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZSP0540
- Development stage
- Preclinical
- Lead developer
- Raynovent Biotech
- Modality
- Small Molecules
01
Overview
ZSP0540 is an investigational small molecule antiviral drug candidate being developed by Raynovent Biotech for the treatment of respiratory syncytial virus (RSV) infection. In preclinical studies, ZSP0540 has demonstrated potent in vitro and in vivo antiviral activity against multiple RSV strains, along with favorable pharmacokinetic properties and low toxicity. The drug is currently in the preclinical/drug discovery phase of development.
Beyond the preview
Go deeper on ZSP0540.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZSP0540.